The Honest Dose #17

This is the seventeenth issue, which puts us just past the four-month mark. I keep marking these little anniversaries, not because the number means anything, but because each one is a chance to check whether the thing I set out to do is still the thing I am actually doing.

Here is what four months of reading this space closely has done to me. It has made me realize, far more than I expected to, how little actually separates the peptide world from the rest of the wellness industry. The people in peptides like to think of themselves as the serious ones. More scientific, more research-backed, more grown-up than the greens powders and the infrared saunas and the water that promises to fix your cells. And in a handful of cases that self-image is earned. But the marketing grammar is identical. A real mechanism at the center, an origin story you want to be true, a confident voice that has something to sell, and a list of benefits that runs three times longer than the evidence underneath it. Swap a peptide for a supplement and the sentence structure does not change. Only the molecule does.

That realization has been uncomfortable, because I do not want this newsletter to be one more voice in that pile, and the honest truth is that the format makes it easy to become one. It is very simple to write about these compounds in a way that borrows the excitement without carrying the caveats, and the excitement is the part that spreads. So I have spent a lot of this month asking myself a plain question. Am I reporting on this space, or am I quietly participating in the thing I keep criticizing?

The reason I care so much about getting that right is that I am not a skeptic. I think some of these compounds are going to matter, genuinely, for ordinary people, in a way that most of what the wellness industry sells never will. I would not spend weekends scoring research logs for a category I thought was noise. But believing something has real potential and being honest about how thin the evidence under it still is are not in tension. Both can be true. The day I let the first one soften the second, this stops being useful and becomes marketing with better footnotes.

So this issue is built directly on that overlap. The lead is the peptide that shows the pattern most clearly from the inside: real biology, a borrowed name, and a recovery reputation resting on human trials that, for the most part, were never run. And the Claim vs Reality is the purest wellness industry version of the exact same move, a real molecule wrapped in a marketing story that oversells it and, remarkably, even points you at the wrong mechanism. Same shape, two different aisles of the same store.

Let's get into it.

If you have spent any time in recovery-focused peptide content, you know TB-500. Often mentioned in the same breath as BPC-157, sold as an accelerant for healing muscles, tendons, and joints. It is one of the most popular compounds in the entire space. It is also one of the clearest examples I can give you of a reputation that belongs to a different molecule than the one in the vial.

What it is, and where the name bends. TB-500 is a synthetic peptide marketed as thymosin beta-4, or TB4, a small protein that occurs naturally throughout your tissues and plays a real role in cell movement, wound healing, and inflammation regulation. Here is the first place the story quietly bends. TB-500 is generally not the full thymosin beta-4 protein. It is typically a shorter synthetic fragment built around TB4's active, actin-binding region, sold under a research-chemical label. The marketing treats "TB-500" and "thymosin beta-4" as the same word. They are related, but they are not identical, and that gap matters because almost all of the credibility attached to the name was earned by the full protein, not by the fragment being sold.

The biology is interesting. Thymosin beta-4 regulates actin, supports the growth of new blood vessels, dampens inflammatory signaling, and helps cells migrate to where repair is needed. Every one of those is directly relevant to healing a strained muscle or a stubborn tendon, which is exactly why the compound is chased for those uses. The mechanism is real. The preclinical literature, the work in cells and in animals, is substantial and compelling. None of that is where this falls apart.

Now the human record. A scoping review published in June 2026 mapped the entire body of thymosin beta-4 and TB-500 research and reached a blunt conclusion: the literature is large, unevenly distributed, and largely preclinical, with only limited human evidence directly relevant to musculoskeletal repair. The human trials that do exist are almost all on recombinant thymosin beta-4, meaning the full protein, and almost all for cardiac indications rather than recovery. There is an early safety and pharmacokinetics study in healthy volunteers, an industry-sponsored trial in heart attack patients, and an earlier cardiac trial that was withdrawn before it ever enrolled anyone. Read that back and notice what is missing. The recovery use that drives essentially all of the consumer interest in TB-500 does not have the controlled human trials that would justify the claims. What human data exists is on a different molecular form, for a different organ, and much of it is funded by the companies developing the drug.

This is borrowed credibility, and it is the same trick every time. The studied thing, recombinant TB4 in cardiac research, is quietly vouching for the unstudied thing, a fragment sold for gym recovery. It is the same structure as Gonadorelin's well-studied fertility history lending its authority to the barely-studied axis-support use, and the same structure as SS-31's rare-disease FDA approval getting laundered into an anti-aging endorsement. The molecule does the science in one room and gets sold in another, and the marketing counts on you not noticing they are different things.

Where it sits right now, is timely. TB-500 is one of the seven peptides the FDA's Pharmacy Compounding Advisory Committee reviewed on July 23 and 24 of this year, and one of the six the committee voted to recommend for the 503A bulks list. That sounds like momentum toward legitimacy, and the marketing will absolutely frame it that way, so hold onto the actual facts. The committee's vote is advisory and nonbinding. The FDA's own reviewers had recommended against adding these substances. No final rule has been issued. TB-500 is not legally compoundable today. And in a detail the "it's basically approved now" crowd will never mention, the FDA separately lists the thymosin beta-4 fragment among bulk substances that may present significant safety risks in compounding, citing exactly the thing this whole section is about: limited human exposure and safety data. Two true facts at once. A committee recommended it, and the agency's own documents flag how little we know. One of those is the headline. The other is the reality.

The score. TB-500 sits at 41 on the Research Quality Score, in the Limited Evidence band. The reason the number lands where it does is not exotic. The human research that would justify the recovery claims has, for the most part, never been run. What exists instead is a strong mechanism, a deep animal literature, and a small set of human trials on a different form of the molecule for a different purpose. That is real science. It is simply not the science being sold to you. As always, the RQS measures research quality and nothing else. It is not a safety rating, it is not an efficacy rating, and it is not me telling you whether this works.

RQS: 41/100 - Limited Evidence

Read the full TB-500 profile

The claim: Ordinary water is a missed opportunity, and the upgrade is a machine or a tablet that turns it into something better. Depending on which version you land on, the water is now alkaline, or ionized, or hydrogen-rich, and those words get used interchangeably as if they mean the same thing. The promised payoff is a familiar wellness stack: powerful antioxidant effects, less inflammation, better hydration, faster recovery, more energy, slower aging, even "detox." The delivery device is often an expensive countertop ionizer or a tube of tablets, and the pitch almost always bundles three separate ideas, pH, ionization, and hydrogen, into one glowing promise.

The reality: This is a more interesting case than a simple debunk, because there is a real molecule and a real mechanism buried in here. That is exactly what makes the overreach effective, and it is the same reason the peptide in today's lead is so easy to sell.

Start by pulling the three claims apart, because the marketing depends on them staying tangled. The only one worth taking seriously is molecular hydrogen, H2. Dissolved hydrogen gas has a legitimate proposed mechanism as a selective antioxidant, meaning it appears to neutralize the most damaging reactive oxygen species while leaving the ones your body uses for signaling alone, along with some anti-inflammatory activity. A 2007 paper in a major journal kicked off the field, and there are now hundreds of studies on it. This is real cell biology, not homeopathy. Something measurable happens.

Now the part the marketing collapses. A real mechanism does not mean the finished product delivers, and the evidence thins out fast the moment you leave the petri dish. Roughly three-quarters of that large literature is in animals. The human trials are small, short, and heterogeneous, and they tend to show modest effects, small reductions in cholesterol and triglycerides in people with metabolic issues, a bit less liver fat over eight weeks, a small aging-marker pilot in older adults that gets described far more breathlessly than its size can support. Every one of them arrives with the same footnote: preliminary, small, more research needed. It is a plausible molecule with modest human support, not a demonstrated miracle.

And here is the correction that matters most, the one that tells you the whole category is mislabeled. The benefit, to whatever extent it is real, is attributed to the dissolved hydrogen, not to the alkalinity and not to the "ionization." A foundational study in this field went out of its way to show that it was the molecular hydrogen, not the alkaline nature of electrolyzed water, that produced the effect. So the single most-marketed word in this space, "alkaline," is pointing you at the wrong mechanism. Your stomach acid neutralizes ingested alkalinity almost immediately regardless, which is what stomach acid is for. Selling alkaline water for its pH is like selling a peptide for a mechanism it does not have. The word is doing the marketing; it is not doing the work.

The delivery problem finishes the story. Hydrogen is the smallest molecule there is, and it escapes water quickly. A lot of ionizer machines and most pre-bottled products deliver little or no meaningful dissolved hydrogen by the time the glass reaches your mouth, and the actual concentration is almost never disclosed. So even in the best case, where hydrogen genuinely helps, a large share of what is sold does not reliably contain the one ingredient the claim rests on. Safety, for the record, is not the issue. Hydrogen is well tolerated and recognized as safe as a beverage ingredient, and that harmlessness is part of why the category runs unchecked. There is nothing scary to disclose, so nothing slows the promises down.

The honest version of the claim: There is a real molecule here, molecular hydrogen, with a specific and legitimate mechanism and a large but mostly preclinical evidence base, plus small human trials showing modest effects on things like blood lipids and liver fat. Wrapped around that real core is a marketing story that oversells the size and certainty of the benefit, misattributes it to "alkaline" or "ionized" when those are not where the mechanism lives, and is often delivered by products that do not contain much hydrogen by the time you drink them. If you enjoy it, it is safe, and that is a perfectly good reason to drink anything. Just know you are buying a plausible mechanism with modest human support, sold under the wrong label, and not the antioxidant miracle printed on the box.

I want to put TB-500 next to BPC-157 this week, because the market treats them as a pair. The two names you hear together in almost every recovery conversation, and the RQS tells you something the pairing hides.

TB-500 scores 41. BPC-157 scores 20. If you only knew that they land near each other, you might assume the two compounds are in the same evidentiary position and that the recovery duo is, at least, evenly matched in how well it is studied. They are not, and the way they arrive at low scores is the interesting part.

BPC-157 is the canonical case of a compound carried by community rather than by trials. Its human research is genuinely thin, and yet the volume of real-world anecdote around it is enormous, arguably larger than any other compound in the catalog. That mountain of firsthand reports is real information of a kind, and it is also precisely the kind of signal the RQS is built to keep in a separate column, because enthusiasm and evidence are different things and collapsing them is how this entire space fools itself. BPC-157's score does not move because thousands of people are convinced, and it should not, because that is not what the number measures.

TB-500 arrives at a low score from a quieter direction. It has the strong mechanism and the deep animal literature, but as the lead laid out, the human trials that exist are on a different molecular form, for a different indication, and the recovery use has essentially no controlled human data at all. So the more famous half of this pair is under-studied but wildly over-discussed, and the other half is relatively studied and comparatively under-scrutinized, riding along on its partner's fame and a borrowed name. Put plainly, the most popular recovery combination in peptides is two compounds that the human research does not yet support, and the one people question least may be the one we know least about.

That is the whole instrument working. The RQS does not reward mechanism, popularity, or a compelling story, it does not treat a committee's recommendation as a verdict, and it keeps community signal in its own lane where a wall of testimonials cannot quietly become "evidence." The number measures research quality and nothing else. It is not a safety rating, it is not an efficacy rating, and it is not me telling you whether either one works.

Compare the recovery compounds on the methodology page

Watch "the FDA recommended it" become "FDA approved" in TB-500 copy. The advisory committee's July vote to recommend six of seven peptides, TB-500 among them, is the most laundered-ready fact in the space right now. The committee is advisory, the vote is nonbinding, the agency's own reviewers had recommended against, no final rule exists, and none of these compounds is legally compoundable today. I would bet on "recommended by an advisory committee" collapsing into "FDA approved" or "now legal" on product pages, with every qualifier that makes it accurate stripped out. When you see it, you are watching a procedural half-step get sold as a finish line. The recommendation is real. The way it gets used in copy is the thing to distrust.

If you compete in anything drug-tested, TB-500 is prohibited. The World Anti-Doping Agency's 2026 Prohibited List includes thymosin beta-4 and its derivatives, TB-500 among them. I flag it as a practical matter for any reader who is a tested athlete, where "it's just a recovery peptide" is not a defense that will help you. It is also a quiet tell about how the compound is categorized by the bodies that actually have to draw lines, which is worth more than any marketing claim about how gentle or natural it is.

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.